Steatotic liver disease is part of a revised nomenclature to replace the term fatty liver disease, but this should also drive forward innovation in research, diagnostics and treatments.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rinella, M. E. et al. Ann. Hepatol. 29, 101133 (2023).
Rinella, M. E. et al. Hepatology 78, 1966–1986 (2023).
Rinella, M. E. et al. J. Hepatol. 79, 1542–1556 (2023).
Ludwig, J. et al. Mayo. Clin. Proc. 55, 434–438 (1980).
Eslam, M. et al. J. Hepatol. 73, 202–209 (2020).
Israelsen, M. et al. Lancet Gastroenterol. Hepatol. 8, 866–868 (2023).
Rasmussen, D. N. et al. J. Hepatol. 75, 1017–1025 (2021).
Sanyal, A. J. et al. N. Engl. J. Med. 385, 1559–1569 (2021).
Kim, R. G. et al. Clin. Gastroenterol. Hepatol. 15, 1521–1530.e8 (2017).
Vilar-Gomez, E. et al. Clin. Gastroenterol. Hepatol. 19, 136–145.e6 (2021).
European Society for Paediatric Gastroenterology & European Association for the Study of the Liver. Lancet Gastroenterol. Hepatol. 8, 598–600 (2023).
Gines, P. et al. Lancet 398, 1359–1376 (2021).
European Association for the Study of the Liver. J. Hepatol. 75, 659–689 (2021).
Kjaergaard, M. et al. J. Hepatol. 79, 277–286 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.K. has served as a speaker for Novo Nordisk, Norgine, Siemens and Nordic Bioscience, has participated in advisory boards for Norgine, Siemens, Resalis Therapeutics, Boehringer Ingelheim and Novo Nordisk, all outside the submitted work, has received research support from Norgine, Siemens, Nordic Bioscience, Astra and Echosens, and is a a board member and co-founder of Evido. M.E.R. serves as a scientific consultant to Novo Nordisk, Boehringer Ingelheim, Intercept, CytoDyn, Histoindex, NGM Bio, GSK, Sonic Incytes, Histoindex and Madrigal.
Rights and permissions
About this article
Cite this article
Krag, A., Rinella, M.E. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med 30, 933–936 (2024). https://doi.org/10.1038/s41591-024-02849-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-024-02849-3